A new methodology was developed which allows to establish rapidly a reliable
diagnostic of genetic diseases such as trisomy 21.
This goal was reached through :
· the design and synthesis of a short probe specific for chromosome 21
centromeric, i.e. not reacting with chromosome n°13 (patents n° PCT/ FR01/
· the setting of an original technique (patent n° PCT/ FR02/ 00762)
during which, in a first step, from a 5 ml sample of maternal blood, more
100 foetal erythroblasts are isolated (80% of purity) and, in a second step,
are identified due to the use of a specific antibody.
To our knowledge this original technology has no equivalent among the
currently used procedures. It reduces delays between the prescription of the
test and the obtention of the results. It can be easily automated to provide
answers for a large population of individuals. It can also be rapidly
adapted to the prenatal diagnosis of other genetic diseases such as
myopathy, cystic fibrosis, thalassemy.....
The inventor of this technology wishes to get in touch with industrial
partners who might be willing to ensure the success of this approach by
taking in charge the marketing and commercial aspects of this activity.
Meetings can be rapidly organized to present results obtained to date.
Exclusive licenses can be granted.
Every serious financial offer will be examined.
Contact: Dr Pierre Commerçon, Lyon, France
Email : pmco69 at free.fr